- Advanced search
- Immuno Portal
- Malaria Portal
Abbreviated name: CBD
Synonyms: Epidiolex® | GWP42003-P | nabiximols (CBD + THC, fixed-doseoral spray) | Sativex® (CBD + THC, fixed-doseoral spray)
cannabidiol is an approved drug (FDA (2018), EMA (2019), UK (2019))
Compound class: Natural product or derivative
Comment: Cannabidiol (CBD) is a natural extract from Cannabis plants (a 'cannabinoid'), which has recently been approved as a much needed therapy for the treatment of orphan pediatric epilepsy syndromes. It may also have benefit in schizophrenia or post-traumatic stress disorder. The major advantage of CBD over other cannabinoids such as Δ9-tetrahydrocannabinol, is that it is devoid of psychotropic effects, whilst retaining analgesic, anti-inflammatory and other beneficial actions.
CBD is also commonly represented with the structure shown by CID 26346.
Ligand Activity Visualisation Charts
These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.✖